| Literature DB >> 30324161 |
In-Sul Hwang1, Mi-Ryung Park1, Tae-Uk Kwak1, Sang-Hyun Park1, Ji-Hyun Lim1, Sung Woo Kim2, Seongsoo Hwang1.
Abstract
To improve survival rates of vitrified pig oocytes, the treatment of cytoskeletal stabilizer on an appropriate time is one of the possible approaches. However, the exact treatment timing and effect of cytoskeletal stabilizer such as cytochalasin B (CB) is not well known during oocyte vitrification procedures. Thus, the present study was conducted to determine optimal treatment timing of CB during vitrification and warming procedures. In experiment 1, the survival rates of the post-warming pig oocytes were analyzed by fluorescein diacetate (FDA) assays with 4 classifications. In results, post-warming oocytes showed significantly (p<0.05) decreased number of alive oocytes (31.8% vs. 86.4%) compared to fresh control. In detail, the significant difference (p<0.05) was found only in strong fluorescence (18.2% vs. 70.5%) not in intermediate fluorescence groups (13.6% vs. 15.9%). In experiment 2, CB was treated before (CB-Vitri) and after (Vitri-CB) vitrification. In results, group of Vitri-CB showed significantly (p<0.05) higher (91.6%) survival rates compared to group of CB-Vitri (83.7%), significantly (p<0.05) and comparable with group of Vitri Control (88.7%) by morphological inspection. In FDA assay results, group of Vitri-CB showed significantly (p<0.05) higher (44.2%) survival rates compared to groups of CB-Vitri (36.7%) and Vitri Control (35.1%). In conclusion, the increased survival rates of post-warming pig oocyte treated with Vitri-CB method are firstly described here. The main finding of present study is that the CB treatment during recovery could be helpful to refresh the post-warming pig oocyte resulting its improved survival rates.Entities:
Keywords: Cryoinjury; Cytochalasin B; Pig oocyte; Viability; Vitrification
Year: 2018 PMID: 30324161 PMCID: PMC6182226 DOI: 10.12717/DR.2018.22.3.245
Source DB: PubMed Journal: Dev Reprod ISSN: 2465-9525
Fig. 1.Categorization of viable post-warming pig oocytes by FDA assay. Oocytes with strong and intermediate signal were determined as alive oocyte while weak and none signal were determined as dead oocyte. FDA, fluorescein diacetate.
Survival rates of post-warming pig oocytes examined by FDA assay
| Groups | No. of oocytes examined | No. of oocytes determined as | |||||
|---|---|---|---|---|---|---|---|
| Alive (%) | Dead (%) | ||||||
| Strong | Intermediate | Total | Weak | None | Total | ||
| Fresh control | 44 | 31 (70.5) | 7 (15.9) | 38 (86.4) | 6(13.6) | 0 (0.0) | 6 (13.6) |
| Post-warming | 44 | 8 (18.2) | 6 (13.6) | 14 (31.8) | 18 (40.9) | 12 (27.3) | 30 (68.2) |
Data are represented as total number (mean) of four replicates in each group.
Different superscripts denote significance within columns (p<0.05).
FDA, fluorescein diacetate.
Effect of Cytochalasin B on viability of post-warming pig oocytes
| Groups | No. of oocytes examined | No. of survived oocytes analyzed by (%) | |
|---|---|---|---|
| Morphology | FDA assay | ||
| Fresh control | 57 | 57 (100±0.0) | 48 (84.2±1.6) |
| Vitri-control | 97 | 86 (88.7±2.8) | 34 (35.1±1.5) |
| CB-Vitri | 98 | 81 (83.7±2.6) | 36 (36.7±1.6) |
| Vitri-CB | 95 | 95 (91.6±2.6) | 42 (44.2±1.0) |
Data are represented as total number (mean±SEM) of four replicates in each group.
Different superscripts denote significance within columns (p<0.05).
FDA, fluorescein diacetate; Vitri-Control, vitrification only; CB-Vitri, CB treatment before vitrification/warming; Vitri-CB, CB treatment after vitrification/warming.